Novo Nordisk's Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
🌍 **Global Health Wins!** New research shows that generic versions of semaglutide could be produced for just $3 a month, potentially transforming access in low- and middle-income countries. Patents are set to expire in India, China, Canada, Brazil, and Turkey this year. This isn't just about affordability — it's about ensuring that more of our global community gets the chance to experience the freedom and health improvements that GLP-1s can bring, regardless of where they live!
Generic versions of Novo Nordisk's blockbuster Wegovy and Ozempic medications could be mass produced for about $3 per person per month, a cost that could greatly widen access in low- and middle-income countries.
Related Articles
What Is Food Noise? The Science Behind GLP-1s and Quiet Minds
Food noise is the constant, intrusive mental chatter about food that millions experience daily. This deep dive explains the neuroscience of how GLP-1 medications like semaglutide and tirzepatide quiet food noise by modulating the hypothalamus and reward pathways, distinguishes food noise from physiological hunger, and provides three evidence-based strategies — trigger-food visibility friction, small-plate pacing, and anchor meal templates — for managing it. Backed by research from JAMA, Cleveland Clinic, and NHS guidance.
Read more →
Why 53.6% of GLP-1 Users Quit Within a Year (And How to Be in the Other Half)
A JAMA Network Open study of 125,474 adults found that 53.6% discontinue GLP-1 medications within one year. This evidence-based analysis examines the six key reasons — side effects, cost, supply shortages, unrealistic expectations, premature cessation, and lack of support structure — and provides clinically-grounded strategies for staying on track, including the Weekly Plateau Scoreboard, Rebound Early-Warning Threshold, and structured side effect management. Anchored by STEP 4 trial data showing 14.8 percentage points difference between continuing and stopping.
Read more →Oral GLP-1 Pills 2026: Wegovy, Foundayo, and Orforglipron Compared
Three oral GLP-1s now have FDA approval: Wegovy pill ($675/mo, Dec 2025), Foundayo orforglipron ($149/mo, April 2026), and Rybelsus (off-label). Trial data shows oral matches injection efficacy within 1-3pp. Here is the full comparison: efficacy, dose timing, side effects, cost.
Read more →Ready to start your GLP-1 journey?
Gila helps you build lasting habits, understand your body, and stay on track. Join the pilot for free.
Join the Pilot